Prevalence of ideal cardiovascular health in the Brazilian adult population - National Health Survey 2019

Abstract Objective: to analyze the prevalence of ideal cardiovascular health (CVH) in the Brazilian adult population based on the 2019 National Health Survey. Methods: this was a population-based cross-sectional study (n = 77,494); prevalence and respective 95% confidence intervals (95%CI) of ideal CVH (seven metrics achieved simultaneously) and by individual metrics (four behavioral and three biological metrics), as defined by the American Heart Association, were estimated. Results: only 0.5% (95%CI 0.4;0.6) of the study population presented ideal CVH, with higher prevalence among those with higher level of education (1.3%; 95%CI 0.9;1.6) and residents in urban areas (0.6%; 95%CI 0.5;0.7); the prevalence of behavioral and biological metrics was 0.7% (95%CI 0.6;0.8) and 63.3% (95%CI 62.7;63.9) respectively. Conclusion: the prevalence of ideal CVH was very low, highlighting the need for public policies aimed at promotion, surveillance and CVH care in the Brazilian adult population

Prevalência de saúde cardiovascular ideal na população adulta brasileira – Pesquisa Nacional de Saúde 2019

Objective: To analyze the prevalence of Ideal Cardiovascular Health (CVH) in the Brazilian adult population based on the 2019 National Health Survey. Methods: Population-based crosssectional study (N=77,494). As proposed by the American Heart Association, the prevalence and 95% confidence intervals (95%CI) of ideal CVH were estimated globally (7 metrics achieved simultaneously) and by individual metrics (four behavioral and three biological). Prevalence was also estimated by sociodemographic characteristics. Results: Only 0.5% (0.4;0.6) of the population presented ideal CVH, with a higher prevalence those with higher education (1.3%; 95%CI 0.9;1.6) and those living in urban areas (0.6%; 0.5;0.7). The prevalence of behavioral and biological metrics was 0.7% (0.6;0.8) and 63.3% (62.7;63.9), respectively. Conclusion: The prevalence of ideal CVH was very low, which highlights the importance of public policies for the promotion, surveillance, and attention to CVH in the Brazilian adult population.Objetivo: Analizar la prevalencia de Salud Cardiovascular (SCV) Ideal en la poblácion adulta brasileña con base en la Encuesta Nacional de Salud de 2019. Métodos: Estudio transversal de base poblacional (n =77,495). Según lo propuesto por la Asociación Americana del Corazón, la prevalencia y los intervalos de confianza del 95% (IC95%) del SCV ideal se estimaron globalmente (siete metas alcanzadas simultáneamente) y por metas individuales (cuatro metas de comportamiento y tres metas). Se calculó la prevalencia de las metas por variables sociodemográficas. Resultados: Sólo el 0,5% (0,4;0,6) de la población presentó SCV ideal, siendo más frecuente en aquellos con educación superior (1,3%; IC95% 0,9;1,6) y entre los residentes de áreas urbanas (0,6%; IC95%0,5;0,7). La prevalencia de las metas de comportamiento y biológicas fue 0,7% (0,6;0,8) y 63,3% (62,7;63,9), respectivamente. Conclusión: La prevalencia de SCV Ideal en adultos brasileños es muy baja,. destacando la necesidad de políticas públicas para la promoción, vigilancia y atención a la SCV en la población adulta brasileña.Objetivo: analisar a prevalência de saúde cardiovascular (SCV) ideal na população adulta brasileira. Métodos: estudo transversal com base na Pesquisa Nacional de Saúde de 2019 (n = 77.494); foram estimadas as prevalências e respectivos intervalos de confiança de 95% (IC95%) de SCV ideal (sete metas alcançadas simultaneamente) e por metas individuais (quatro metas comportamentais; três biológicas), conforme propõe a Associação Americana do Coração. Resultados: apenas 0,5% (IC95% 0,4;0,6) da população estudada apresentou SCV ideal, observando-se maior prevalência entre aqueles com maior escolaridade (1,3% – IC95% 0,9;1,6)  e os residentes em áreas urbanas (0,6% – IC95% 0,5;0,7); as prevalências das metas comportamentais e biológicas foram de 0,7% (IC95% 0,6;0,8) e 63,3% (IC95% 62,7;63,9) respectivamente. Conclusão: a prevalência de SCV ideal foi muito baixa, evidenciando a necessidade de políticas públicas para promoção, vigilância e atenção à SCV na população adulta brasileira

Social Networks Shape the Transmission Dynamics of Hepatitis C Virus

Hepatitis C virus (HCV) infects 170 million people worldwide, and is a major public health problem in Brazil, where over 1% of the population may be infected and where multiple viral genotypes co-circulate. Chronically infected individuals are both the source of transmission to others and are at risk for HCV-related diseases, such as liver cancer and cirrhosis. Before the adoption of anti-HCV control measures in blood banks, this virus was mainly transmitted via blood transfusion. Today, needle sharing among injecting drug users is the most common form of HCV transmission. Of particular importance is that HCV prevalence is growing in non-risk groups. Since there is no vaccine against HCV, it is important to determine the factors that control viral transmission in order to develop more efficient control measures. However, despite the health costs associated with HCV, the factors that determine the spread of virus at the epidemiological scale are often poorly understood. Here, we sequenced partial NS5b gene sequences sampled from blood samples collected from 591 patients in São Paulo state, Brazil. We show that different viral genotypes entered São Paulo at different times, grew at different rates, and are associated with different age groups and risk behaviors. In particular, subtype 1b is older and grew more slowly than subtypes 1a and 3a, and is associated with multiple age classes. In contrast, subtypes 1a and 3b are associated with younger people infected more recently, possibly with higher rates of sexual transmission. The transmission dynamics of HCV in São Paulo therefore vary by subtype and are determined by a combination of age, risk exposure and underlying social network. We conclude that social factors may play a key role in determining the rate and pattern of HCV spread, and should influence future intervention policies

Outcomes and risk score for distal pancreatectomy with celiac axis resection (DP-CAR) : an international multicenter analysis

Background: Distal pancreatectomy with celiac axis resection (DP-CAR) is a treatment option for selected patients with pancreatic cancer involving the celiac axis. A recent multicenter European study reported a 90-day mortality rate of 16%, highlighting the importance of patient selection. The authors constructed a risk score to predict 90-day mortality and assessed oncologic outcomes. Methods: This multicenter retrospective cohort study investigated patients undergoing DP-CAR at 20 European centers from 12 countries (model design 2000-2016) and three very-high-volume international centers in the United States and Japan (model validation 2004-2017). The area under receiver operator curve (AUC) and calibration plots were used for validation of the 90-day mortality risk model. Secondary outcomes included resection margin status, adjuvant therapy, and survival. Results: For 191 DP-CAR patients, the 90-day mortality rate was 5.5% (95 confidence interval [CI], 2.2-11%) at 5 high-volume (1 DP-CAR/year) and 18% (95 CI, 9-30%) at 18 low-volume DP-CAR centers (P=0.015). A risk score with age, sex, body mass index (BMI), American Society of Anesthesiologists (ASA) score, multivisceral resection, open versus minimally invasive surgery, and low- versus high-volume center performed well in both the design and validation cohorts (AUC, 0.79 vs 0.74; P=0.642). For 174 patients with pancreatic ductal adenocarcinoma, the R0 resection rate was 60%, neoadjuvant and adjuvant therapies were applied for respectively 69% and 67% of the patients, and the median overall survival period was 19months (95 CI, 15-25months). Conclusions: When performed for selected patients at high-volume centers, DP-CAR is associated with acceptable 90-day mortality and overall survival. The authors propose a 90-day mortality risk score to improve patient selection and outcomes, with DP-CAR volume as the dominant predictor

Author Correction: Mendelian neurodegenerative disease genes involved in autophagy

An amendment to this paper has been published and can be accessed via a link at the top of the paper

Mendelian neurodegenerative disease genes involved in autophagy

Funder: Fondation Roger de Spoelberch (Roger de Spoelberch Foundation); doi: https://doi.org/10.13039/501100008236Funder: Alzheimer's Research UK (ARUK); doi: https://doi.org/10.13039/501100002283Funder: UK Dementia Research InstituteFunder: Takeda Science Foundation; doi: https://doi.org/10.13039/100007449Abstract: The lysosomal degradation pathway of macroautophagy (herein referred to as autophagy) plays a crucial role in cellular physiology by regulating the removal of unwanted cargoes such as protein aggregates and damaged organelles. Over the last five decades, significant progress has been made in understanding the molecular mechanisms that regulate autophagy and its roles in human physiology and diseases. These advances, together with discoveries in human genetics linking autophagy-related gene mutations to specific diseases, provide a better understanding of the mechanisms by which autophagy-dependent pathways can be potentially targeted for treating human diseases. Here, we review mutations that have been identified in genes involved in autophagy and their associations with neurodegenerative diseases

Erratum: Author Correction: Mendelian neurodegenerative disease genes involved in autophagy.

[This corrects the article DOI: 10.1038/s41421-020-0158-y.]

Combining Asian and European genome-wide association studies of colorectal cancer improves risk prediction across racial and ethnic populations

Polygenic risk scores (PRS) have great potential to guide precision colorectal cancer (CRC) prevention by identifying those at higher risk to undertake targeted screening. However, current PRS using European ancestry data have sub-optimal performance in non-European ancestry populations, limiting their utility among these populations. Towards addressing this deficiency, we expand PRS development for CRC by incorporating Asian ancestry data (21,731 cases; 47,444 controls) into European ancestry training datasets (78,473 cases; 107,143 controls). The AUC estimates (95% CI) of PRS are 0.63(0.62-0.64), 0.59(0.57-0.61), 0.62(0.60-0.63), and 0.65(0.63-0.66) in independent datasets including 1681-3651 cases and 8696-115,105 controls of Asian, Black/African American, Latinx/Hispanic, and non-Hispanic White, respectively. They are significantly better than the European-centric PRS in all four major US racial and ethnic groups (p-values < 0.05). Further inclusion of non-European ancestry populations, especially Black/African American and Latinx/Hispanic, is needed to improve the risk prediction and enhance equity in applying PRS in clinical practice